KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) FCF Margin (2016 - 2025)

Pacira BioSciences has reported FCF Margin over the past 16 years, most recently at 29.12% for Q4 2025.

  • Quarterly results put FCF Margin at 29.12% for Q4 2025, up 1418.0% from a year ago — trailing twelve months through Dec 2025 was 20.72% (down 550.0% YoY), and the annual figure for FY2025 was 20.72%, down 550.0%.
  • FCF Margin for Q4 2025 was 29.12% at Pacira BioSciences, down from 31.73% in the prior quarter.
  • Over the last five years, FCF Margin for PCRX hit a ceiling of 49.85% in Q3 2021 and a floor of 8.46% in Q4 2022.
  • Median FCF Margin over the past 5 years was 20.07% (2021), compared with a mean of 20.49%.
  • Peak annual rise in FCF Margin hit 5393bps in 2021, while the deepest fall reached -3314bps in 2021.
  • Pacira BioSciences' FCF Margin stood at 13.26% in 2021, then crashed by -164bps to 8.46% in 2022, then surged by 321bps to 18.7% in 2023, then decreased by -20bps to 14.94% in 2024, then soared by 95bps to 29.12% in 2025.
  • The last three reported values for FCF Margin were 29.12% (Q4 2025), 31.73% (Q3 2025), and 5.14% (Q2 2025) per Business Quant data.